Xilio Therapeutics (XLO) Operating Expenses (2020 - 2026)

Xilio Therapeutics has disclosed Operating Expenses across 7 years of filings, most recently posting $22.2 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 1.19% year-over-year to $22.2 million; the TTM figure through Jun 2026 stood at $95.5 million (up 33.31% YoY), while the FY2025 annual figure was $85.7 million, up 28.12% from the prior year.
• Operating Expenses came in at $22.2 million for Q2 2026 at Xilio Therapeutics, down from $26.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $26.8 million in Q1 2026 to a low of $15.4 million in Q4 2024.
• Average Operating Expenses over 5 years is $20.5 million, with a median of $20.6 million recorded in 2022.
• Year-over-year, Operating Expenses slipped 25.67% in 2024 and jumped 66.23% in 2025.
• Over 5 years, Operating Expenses stood at $23.2 million in 2022, then decreased by 21.74% to $18.1 million in 2023, then retreated by 15.32% to $15.4 million in 2024, then jumped by 66.23% to $25.5 million in 2025, then retreated by 13.08% to $22.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $22.2 million in Q2 2026, $26.8 million in Q1 2026, and $25.5 million in Q4 2025.